146 related articles for article (PubMed ID: 8100625)
1. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Barnebey HS; Robin AL; Zimmerman TJ; Morrison JC; Hersh SB; Lewis RA; Coleman AL; Cinotti DJ; Walt J; Chen KS
Ophthalmology; 1993 Jul; 100(7):1083-8. PubMed ID: 8100625
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
[TBL] [Abstract][Full Text] [Related]
3. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
Ma YR; Lee BH; Yang KJ; Park YG
Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
[TBL] [Abstract][Full Text] [Related]
5. Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group.
Ophthalmic Surg Lasers; 1995; 26(5):404-9. PubMed ID: 8963853
[TBL] [Abstract][Full Text] [Related]
6. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Barnes SD; Campagna JA; Dirks MS; Doe EA
Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
8. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
9. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB
Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of intraocular pressure elevation after argon laser trabeculoplasty in primary open angle glaucoma].
Bozić M; Hentova-Senćić P; Kontić D; Marković V; Marjanović I
Srp Arh Celok Lek; 2011; 139(1-2):12-7. PubMed ID: 21568077
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
16. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
18. Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy.
Gartaganis SP; Mela EK; Katsimpris JM; Petropoulos JK; Karamanos NK; Koliopoulos JX
Ophthalmic Surg Lasers; 1999; 30(8):647-52. PubMed ID: 10507567
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification.
Katsimpris JM; Siganos D; Konstas AG; Kozobolis V; Georgiadis N
J Cataract Refract Surg; 2003 Dec; 29(12):2288-94. PubMed ID: 14709288
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine and postoperative pressure spikes in cataract surgery.
Whitehouse G
Clin Exp Ophthalmol; 2000 Oct; 28(5):364-6. PubMed ID: 11097284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
